Advancing Care for Diabetic Macular Edema
Research Highlights Long-Term Benefits of Higher-Dose Aflibercept for Diabetic Macular Edema
Diabetic macular edema (DME) is a common complication of diabetes that can lead to blurred vision and vision loss when fluid accumulates in the retina. While treatment advances have helped many patients preserve their sight, researchers continue to explore ways to provide lasting results with fewer treatment visits.
Research presented by Dr. Eric Schneider examined the long-term effectiveness of aflibercept 8 mg, a higher-dose treatment option for patients with DME.
The study found that patients receiving aflibercept 8 mg maintained both visual and anatomical improvements over an extended follow-up period. Many patients were able to achieve treatment intervals of 12 weeks or longer, and nearly half reached intervals of 20 weeks or more between injections.
Researchers also observed that retinal fluid returned more slowly in patients who transitioned from lower-dose treatment to the higher-dose therapy, suggesting a longer duration of treatment effect.
Importantly, no new safety concerns were identified during the extended study period.
These findings support the growing body of evidence that higher-dose aflibercept may help some patients maintain strong treatment outcomes while extending the time between treatments.
At Tennessee Retina, our physicians remain actively engaged in advancing retinal care through research, education, and the adoption of evidence-based treatments designed to preserve and improve vision.
If you have questions about diabetic macular edema or available treatment options, speak with your retina specialist to learn what approach may be right for you.
Read the full Abstract HERE
